51 recruiting. 51 Phase 2, 7 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 51 | Recruiting 51 |
| Phase 1 | 7 | Recruiting 7 |
| Phase 3 | 5 | Recruiting 5 |
Follow Colitis, Ulcerative: new trials by email Literature Review of Colitis, Ulcerative trials Research Report on Colitis, Ulcerative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aquamin® for Prevention of Ulcerative Colitis J-Pouch-associate Intestinal Inflammation Aquamin - Ulcerative Colitis, Ileal Pouch | Phase 2 | Recruiting | Muhammad N Aslam, MD | 52 | 2026-11-01 | 2026-11-02 |
| Nitazoxanide as Adjunct Therapy in Mild-to-Moderate Ulcerative Colitis Nitazoxanide (NTZ) - Ulcerative Colitis (UC) | Phase 2 / Phase 3 | Recruiting | Tanta University | 44 | 2026-10-25 | 2026-11-09 |
| A Study of AC-101 Tablets in Patients With Ulcerative Colitis AC-101, Placebo - Ulcerative Colitis (UC) | Phase 2 | Recruiting | Accro Bioscience (Suzhou) Limited | 153 | 2026-09-10 | 2026-10-28 |
| A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis PALI-2108, Placebo - Ulcerative Colitis (UC), Severe Ulcerative Colitis | Phase 2 | Recruiting | Palisade Bio | 204 | 2026-08-28 | 2026-10-21 |
| Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial) Modafinil, Placebo - Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Chronic Fatigue | Phase 2 / Phase 3 | Recruiting | Radboud University Medical Center | 60 | 2026-08-03 | 2026-09-14 |
| Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis Risankizumab, Trosunilimab, ABBV-701 - Crohn's Disease, Ulcerative Colitis | Phase 2 | Recruiting | AbbVie | 2000 | 2026-07-31 | 2026-10-27 |
| Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study) MGT-006, Vancomycin hydrochloride, Amoxicillin hydrate/ Fosfomycin calcium hydrate/ Metronidazole - Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate | Phase 1 / Phase 2 | Recruiting | Metagen Therapeutics, Inc. | 54 | 2026-07-09 | 2026-11-03 |
| Investigation of Vancomycin Efficacy in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Placebo (blinded), Vancomycin (blinded), Vancomycin (open-label extension) - Ulcerative Colitis (UC), Primary Sclerosing Cholangitis (PSC) | Phase 2 | Recruiting | McMaster University | 14 | 2026-06-17 | 2026-10-09 |
| A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis INT-210 Capsule - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Innatus Therapeutics (Shanghai) Co., Ltd. | 24 | 2026-06-11 | 2026-07-09 |
| A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis Etrasimod - Colitis, Ulcerative | Phase 2 | Recruiting | Pfizer | 24 | 2026-05-28 | 2026-10-26 |
| A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089 - Colitis, Ulcerative, Crohn Disease | Phase 2 | Recruiting | Eli Lilly and Company | 60 | 2026-05-04 | 2026-11-04 |
| Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC) ATH-063, Placebo - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Recruiting | Athos Therapeutics Inc | 120 | 2026-04-30 | 2026-09-21 |
| Selenium Supplementation in Moderate-Severely Active Ulcerative Colitis Patients Treated With Advanced Therapies Selenium supplementation, Placebo - Ulcerative Colitis (UC) | Phase 2 | Recruiting | Northwestern University | 180 | 2026-04-29 | 2026-05-22 |
| Confirmatory Clinical Study in Active Ulcerative Colitis Low-dose MH002, High-dose MH002, Placebo - Colitis, Ulcerative | Phase 2 | Recruiting | MRM Health NV | 204 | 2026-04-03 | 2026-10-21 |
| A Study of MB-001 in Moderately to Severely Active Ulcerative Colitis MB-001, Matching placebo to MB-001 - Ulcerative Colitis (UC) | Phase 1 / Phase 2 | Recruiting | Mage Biologics | 100 | 2026-04-01 | 2026-10-20 |
| The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC 627, Placebo - Ulcerative Colitis (UC) | Phase 2 | Recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 288 | 2026-03-28 | 2026-07-28 |
| LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis LY4268989, Placebo - Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate | Phase 2 | Recruiting | Eli Lilly and Company | 1431 | 2026-03-26 | 2026-11-04 |
| A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002) MK-8690, Placebo - Colitis Ulcerative, Ulcerative Colitis | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 100 | 2026-03-24 | 2026-10-23 |
| Fecal Microbiota Transplantation for Ulcerative Colitis Using Dai and Han Donors Fecal Microbiota Transplantation (FMT) - Ulcerative Colitis (UC), Inflammatory Bowel Disease | Phase 2 | Recruiting | First Affiliated Hospital of Kunming Medical University | 200 | 2026-02-03 | 2026-09-15 |
| A Study for HSK47388 in Participants With Ulcerative Colitis HSK47388, Placebo - Ulcerative Colitis (UC) | Phase 2 | Recruiting | Haisco Pharmaceutical Group Co., Ltd. | 150 | 2026-02-03 | 2026-03-05 |
Showing 20 of 51. Sign in to see all of them.
Inflammatory Bowel Diseases (11) · Crohn Disease (7) · Colitis (6) · Ulcer (2) · Adenocarcinoma Of Esophagus (1) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Carcinoma, Squamous Cell (1) · Cholangitis, Sclerosing (1) · Colonic Neoplasms (1)
Colonic Diseases (51) · Digestive System Diseases (51) · Gastroenteritis (51) · Gastrointestinal Diseases (51) · Intestinal Diseases (51) · Colitis (45) · Inflammatory Bowel Diseases (40) · Pathological Conditions, Signs and Symptoms (4) · Immune System Diseases (2) · Pathologic Processes (2) · Signs and Symptoms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Adenocarcinoma (1) · Ankylosis (1)
Mesalamine (5) · Fecal Microbiota Transplantation (4) · Vancomycin (3) · etrasimod (2) · mirikizumab (2) · nitazoxanide (2) · Amphotericin B (1) · Aquamin (1) · Azathioprine (1) · Butyrates (1) · Infliximab (1) · Inulin (1) · Metronidazole (1) · Modafinil (1) · Nivolumab (1)
Eli Lilly and Company (3) · Tanta University (3) · Alexandria University (2) · Brigham and Women's Hospital (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · Pfizer (2) · AbbVie (1) · Accro Bioscience (Suzhou) Limited (1) · Assistance Publique - Hôpitaux de Paris (1) · Athos Therapeutics Inc (1) · Biocad (1) · Boehringer Ingelheim (1) · Bristol-Myers Squibb (1) · Children's Hospital Los Angeles (1) · Diwakar Davar (1)
United States (25) · Poland (17) · Canada (15) · China (13) · Italy (10) · Japan (9) · Czechia (8) · France (8) · Germany (8) · Hungary (7) · Ukraine (7) · Australia (6) · Brazil (6) · Georgia (6) · Israel (6)
Arina V Zinkina-Orikhan (1) · Dalia R Mohammed ElAfify, Asst.Prof (1) · David T. Rubin, MD (1) · Diwakar J Davar, MD (1) · Faming Zhang, PhD (1) · Gianluca Ianiro (1) · Gianluca Ianiro, MD (1)
PMID 35379276, PMID 36424592, PMID 36581160, PMID 37704113
2025 (5), 2023 (3), R01DK144103 (1)